Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-21

AUTHORS

Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan

ABSTRACT

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3. METHODS: Utilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens. RESULTS: In the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817. CONCLUSIONS: When compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection. More... »

PAGES

15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4

DOI

http://dx.doi.org/10.1186/s12962-017-0077-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090851960

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28736505


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Human & Health Sciences, Swansea University, Swansea, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK", 
            "School of Human & Health Sciences, Swansea University, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Webster", 
        "givenName": "Samantha", 
        "id": "sg:person.01165715264.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ward", 
        "givenName": "Thomas", 
        "id": "sg:person.01003353464.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UK HEOR, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "UK HEOR, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brenner", 
        "givenName": "Michael", 
        "id": "sg:person.01234030464.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalsekar", 
        "givenName": "Anupama", 
        "id": "sg:person.01247570417.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Yong", 
        "id": "sg:person.01253410531.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40258-012-0002-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008579116", 
          "https://doi.org/10.1007/s40258-012-0002-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-016-0865-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005166928", 
          "https://doi.org/10.1007/s10198-016-0865-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-21", 
    "datePublishedReg": "2017-07-21", 
    "description": "BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.\nMETHODS: Utilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12\u00a0weeks of treatment with daclatasvir\u00a0+\u00a0sofosbuvir (DCV\u00a0+\u00a0SOF) was compared to 24\u00a0weeks of treatment with sofosbuvir\u00a0+\u00a0ribavirin (SOF\u00a0+\u00a0RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.\nRESULTS: In the base case analysis, DCV\u00a0+\u00a0SOF was found to be dominant over SOF\u00a0+\u00a0RBV in treatment-na\u00efve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV\u00a0+\u00a0SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of \u00a38817.\nCONCLUSIONS: When compared to 24\u00a0weeks of SOF\u00a0+\u00a0RBV, 12\u00a0weeks of treatment with DCV\u00a0+\u00a0SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12962-017-0077-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "weeks of treatment", 
      "interferon-containing regimens", 
      "direct acting antivirals", 
      "treatment options", 
      "genotype 3", 
      "genotype 3 hepatitis C virus", 
      "hepatitis C virus genotype 3", 
      "genotype 3 HCV infection", 
      "incremental cost-effectiveness ratio", 
      "chronic hepatitis C", 
      "interferon-free regimens", 
      "HCV genotype 3", 
      "treatment-na\u00efve patients", 
      "matching-adjusted indirect comparison", 
      "hepatitis C virus", 
      "virus genotype 3", 
      "faster disease progression", 
      "clinical trial data", 
      "cost-effectiveness ratio", 
      "base-case analysis", 
      "cost-utility analysis", 
      "HCV infection", 
      "hepatitis C", 
      "intolerant patients", 
      "HCV genotypes", 
      "C virus", 
      "disease progression", 
      "indirect comparison", 
      "patients", 
      "regimens", 
      "trial data", 
      "sofosbuvir", 
      "weeks", 
      "treatment", 
      "ribavirin", 
      "daclatasvir", 
      "lower rates", 
      "improved quality", 
      "RBV", 
      "SOF", 
      "DCV", 
      "options", 
      "antivirals", 
      "infection", 
      "appropriate allocation", 
      "progression", 
      "virus", 
      "total cost", 
      "high cost", 
      "genotypes", 
      "analysis", 
      "life", 
      "rate", 
      "case analysis", 
      "UK", 
      "data", 
      "quality", 
      "ratio", 
      "comparison", 
      "results", 
      "Markov model", 
      "cost", 
      "values", 
      "model", 
      "model inputs", 
      "input", 
      "resources", 
      "allocation", 
      "economic value", 
      "C virus (HCV) genotype 3", 
      "UK-specific model inputs", 
      "weeks of SOF"
    ], 
    "name": "Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus", 
    "pagination": "15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090851960"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12962-017-0077-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28736505"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12962-017-0077-4", 
      "https://app.dimensions.ai/details/publication/pub.1090851960"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_723.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12962-017-0077-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      100 URIs      90 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12962-017-0077-4 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N56a1ae5df5a34ea3b7d869b2ccc11b19
4 schema:citation sg:pub.10.1007/s10198-016-0865-3
5 sg:pub.10.1007/s40258-012-0002-0
6 schema:datePublished 2017-07-21
7 schema:datePublishedReg 2017-07-21
8 schema:description BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3. METHODS: Utilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens. RESULTS: In the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817. CONCLUSIONS: When compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree true
12 schema:isPartOf N538f70b76b544e29a946c6195912e923
13 N89965256291446a09d8c5a8c1a6cc336
14 sg:journal.1032048
15 schema:keywords C virus
16 C virus (HCV) genotype 3
17 DCV
18 HCV genotype 3
19 HCV genotypes
20 HCV infection
21 Markov model
22 RBV
23 SOF
24 UK
25 UK-specific model inputs
26 allocation
27 analysis
28 antivirals
29 appropriate allocation
30 base-case analysis
31 case analysis
32 chronic hepatitis C
33 clinical trial data
34 comparison
35 cost
36 cost-effectiveness ratio
37 cost-utility analysis
38 daclatasvir
39 data
40 direct acting antivirals
41 disease progression
42 economic value
43 faster disease progression
44 genotype 3
45 genotype 3 HCV infection
46 genotype 3 hepatitis C virus
47 genotypes
48 hepatitis C
49 hepatitis C virus
50 hepatitis C virus genotype 3
51 high cost
52 improved quality
53 incremental cost-effectiveness ratio
54 indirect comparison
55 infection
56 input
57 interferon-containing regimens
58 interferon-free regimens
59 intolerant patients
60 life
61 lower rates
62 matching-adjusted indirect comparison
63 model
64 model inputs
65 options
66 patients
67 progression
68 quality
69 rate
70 ratio
71 regimens
72 resources
73 results
74 ribavirin
75 sofosbuvir
76 total cost
77 treatment
78 treatment options
79 treatment-naïve patients
80 trial data
81 values
82 virus
83 virus genotype 3
84 weeks
85 weeks of SOF
86 weeks of treatment
87 schema:name Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
88 schema:pagination 15
89 schema:productId N1799b286df4d4b70b393df3a428745da
90 N61039f94cffe4f55a48172e7682fb017
91 N70fe61d8b7734eca88d0f15ded0afa98
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090851960
93 https://doi.org/10.1186/s12962-017-0077-4
94 schema:sdDatePublished 2021-11-01T18:28
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N7baa0bad8da14456b5be09bcf9ea6fb3
97 schema:url https://doi.org/10.1186/s12962-017-0077-4
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N145e05d1b94246028d73fe6a3bc603de rdf:first sg:person.01003353464.51
102 rdf:rest N6f6cbf4a0a6f4fba90d16cc606194b2e
103 N1799b286df4d4b70b393df3a428745da schema:name pubmed_id
104 schema:value 28736505
105 rdf:type schema:PropertyValue
106 N3e00eed28b1441ecb04b9c7efbf6d41b rdf:first sg:person.01247570417.25
107 rdf:rest Nbc8d3fde86f04f9b91ab0dcf8867ee55
108 N538f70b76b544e29a946c6195912e923 schema:issueNumber 1
109 rdf:type schema:PublicationIssue
110 N56a1ae5df5a34ea3b7d869b2ccc11b19 rdf:first sg:person.01346767345.38
111 rdf:rest Nc3a57c59d5c44799af370c1d68090e5e
112 N61039f94cffe4f55a48172e7682fb017 schema:name dimensions_id
113 schema:value pub.1090851960
114 rdf:type schema:PropertyValue
115 N6f6cbf4a0a6f4fba90d16cc606194b2e rdf:first sg:person.01234030464.96
116 rdf:rest N3e00eed28b1441ecb04b9c7efbf6d41b
117 N70fe61d8b7734eca88d0f15ded0afa98 schema:name doi
118 schema:value 10.1186/s12962-017-0077-4
119 rdf:type schema:PropertyValue
120 N7baa0bad8da14456b5be09bcf9ea6fb3 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N89965256291446a09d8c5a8c1a6cc336 schema:volumeNumber 15
123 rdf:type schema:PublicationVolume
124 Nbc8d3fde86f04f9b91ab0dcf8867ee55 rdf:first sg:person.01253410531.33
125 rdf:rest rdf:nil
126 Nc3a57c59d5c44799af370c1d68090e5e rdf:first sg:person.01165715264.65
127 rdf:rest N145e05d1b94246028d73fe6a3bc603de
128 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
129 schema:name Economics
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
132 schema:name Applied Economics
133 rdf:type schema:DefinedTerm
134 sg:journal.1032048 schema:issn 1478-7547
135 schema:name Cost Effectiveness and Resource Allocation
136 schema:publisher Springer Nature
137 rdf:type schema:Periodical
138 sg:person.01003353464.51 schema:affiliation grid-institutes:None
139 schema:familyName Ward
140 schema:givenName Thomas
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51
142 rdf:type schema:Person
143 sg:person.01165715264.65 schema:affiliation grid-institutes:None
144 schema:familyName Webster
145 schema:givenName Samantha
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65
147 rdf:type schema:Person
148 sg:person.01234030464.96 schema:affiliation grid-institutes:None
149 schema:familyName Brenner
150 schema:givenName Michael
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96
152 rdf:type schema:Person
153 sg:person.01247570417.25 schema:affiliation grid-institutes:grid.419971.3
154 schema:familyName Kalsekar
155 schema:givenName Anupama
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25
157 rdf:type schema:Person
158 sg:person.01253410531.33 schema:affiliation grid-institutes:grid.419971.3
159 schema:familyName Yuan
160 schema:givenName Yong
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33
162 rdf:type schema:Person
163 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
164 schema:familyName McEwan
165 schema:givenName Phil
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
167 rdf:type schema:Person
168 sg:pub.10.1007/s10198-016-0865-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005166928
169 https://doi.org/10.1007/s10198-016-0865-3
170 rdf:type schema:CreativeWork
171 sg:pub.10.1007/s40258-012-0002-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008579116
172 https://doi.org/10.1007/s40258-012-0002-0
173 rdf:type schema:CreativeWork
174 grid-institutes:None schema:alternateName Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK
175 UK HEOR, Bristol–Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
176 schema:name Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK
177 UK HEOR, Bristol–Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
178 rdf:type schema:Organization
179 grid-institutes:grid.419971.3 schema:alternateName World Wide Health Economics and Outcomes Research, Bristol–Myers Squibb Pharmaceuticals Ltd, Princeton, USA
180 schema:name World Wide Health Economics and Outcomes Research, Bristol–Myers Squibb Pharmaceuticals Ltd, Princeton, USA
181 rdf:type schema:Organization
182 grid-institutes:grid.4827.9 schema:alternateName School of Human & Health Sciences, Swansea University, Swansea, UK
183 schema:name Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK
184 School of Human & Health Sciences, Swansea University, Swansea, UK
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...